FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC

Share this content:
The FDA grants Priority Review to medications with the potential to significantly improve outcomes or safety in the treatment, diagnosis, or prevention of serious conditions compared with available tr
The FDA grants Priority Review to medications with the potential to significantly improve outcomes or safety in the treatment, diagnosis, or prevention of serious conditions compared with available tr

The US Food and Drug Administration (FDA) granted Priority Review to afatinib as first-line treatment for patients with non–small cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) exon 21 (L861Q), G719X, or S768I substitution mutations.1

These mutations are present in approximately 10% of patients with EGFR-positive NSCLC and are associated with significantly worse outcomes.

The FDA based its approval on findings from a meta-analysis of 3 trials from the LUX-Lung clinical trial program. A post-hoc analysis published in The Lancet Oncology presented data from the LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 studies, for which researchers prospectively analyzed data from 75 EGFR TKI–naive patients with uncommon EGFR-positive NSCLC.2

Among patients with the point mutations or duplications in exons 18 to 21, 71.1% (21) treated with afatinib had an objective response (95% CI, 54.1%-84.6%). Median progression-free survival was 10.7 months (95% CI, 5.6-14.7), and median overall survival was 19.4 months (95% CI, 16.4-26.9).

The FDA grants Priority Review to medications with the potential to significantly improve outcomes or safety in the treatment, diagnosis, or prevention of serious conditions compared with available treatments.

References

  1. FDA grants Priority Review to Gilotrif® for uncommon EGFR mutations in advanced NSCLC [news release]. Ridgefield, CT: Boehringer Ingelheim; October 10, 2017. https://www.boehringer-ingelheim.us/press-release/fda-grants-priority-review-gilotrif-uncommon-egfr-mutations-advanced-nsclc. Accessed October 10, 2017.
  2. Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830-8.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters